(Q33363695)

English

Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yukio Kobayashi

object named as

Yukio Kobayashi

3

0 references

14

object named as

Kensei Tobinai

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

9

object named as

Tohru Murayama

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Michinori Ogura

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yasuo Morishima

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Naokuni Uike

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Susumu Sugai

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Takaaki Chou

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Masaharu Kasai

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ikuo Miura

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yoshihiro Matsuno

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Shigeo Nakamura

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Shigeo Mori

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yasuo Ohashi

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cladribine Study Group

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 October 2004

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

80

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

267-277

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1532/ijh97.04077

0 references

A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subsequent cancer in patients with chronic lymphocytic leukemia--a possible immunologic mechanism

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of prognostic factors in follicular lymphoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibody against PRAD1/cyclin D1 stains nuclei of tumor cells with translocation or amplification at BCL-1 locus

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subsequent Neoplasia in Chronic Lymphocytic Leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA)

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoposide and secondary haematological malignancies: coincidence or causality?

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second malignancies in hairy cell leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL)

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cladribine (2-chlorodeoxyadenosine)

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas: challenges and opportunities

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination versus successive single agent chemotherapy in lymphocytic lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2-Chlorodeoxyadenosine treatment of low-grade lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunohistochemical analysis of cyclin D1 protein in hematopoietic neoplasms with special reference to mantle cell lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The natural history of initially untreated low-grade non-Hodgkin's lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15540903

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1532/IJH97.04077

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

release_lg62k2letrfspbtfrxdbufbe3q

1 reference

https://api.fatcat.wiki/v0/release/lg62k2letrfspbtfrxdbufbe3q

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33363695&oldid=2107099339"